Tissue Dynamics and Galmed Collaborate on Cardiac Fibrosis Model

AI Summary

Tissue Dynamics and Galmed Pharmaceuticals (GLMD) have formed a partnership to develop a cardiac fibrosis model. This collaboration aims to enhance the understanding of heart conditions associated with fibrosis. The scientific advancements from this model could impact drug development and treatment strategies in cardiology. This partnership may lead to potential market opportunities in therapies targeting cardiac health.